Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Updated version 2 - Eli Lilly will acquire Calytrix for up to $1.5 billion, betting on the field of rare blood cancers.

Updated version 2 - Eli Lilly will acquire Calytrix for up to $1.5 billion, betting on the field of rare blood cancers.

路透社路透社2026/11/16 15:30
Show original

The full text includes additional details and background information.

- Eli Lilly (LLY.N) has agreed to acquire private biotech company Calytrix Bio for up to $1.5 billion in cash, aiming to expand its development of treatments for rare blood cancers.

Calytrix announced the move on Monday, marking the latest in a series of recent acquisitions by the Indianapolis-based pharmaceutical giant as it seeks to move beyond its best-selling diabetes and weight-loss drugs and diversify its business.

Eli Lilly shares rose 1.4% in early trading.

https://www.reuters.com/graphics/LILLY-DEALS/LILLY-DEALS/byprnyrzdpe/chart.png

The deal is expected to reinforce Lilly’s presence in hematology by adding an experimental therapy to its portfolio, which already includes Jaypirca, a blood cancer drug approved by the U.S. Food and Drug Administration (FDA). Earlier this year, Lilly also acquired Ajax Therapeutics for $2.3 billion (link), furthering its strategic moves in the blood cancer field.

Calytrix stated that the deal includes an upfront payment, as well as additional payments tied to clinical and regulatory milestones. The company did not disclose the specific amount of the upfront payment nor when the deal is expected to close.

Calytrix’s lead candidate is an early-stage antibody therapy for primary thrombocythemia and myelofibrosis—two rare blood diseases that cause the bone marrow to produce excessive abnormal blood cells. The drug has not yet entered human clinical trials.

This therapy targets mutated calreticulin, a genetic alteration that is a primary cause of these blood diseases. According to Calytrix, the therapy aims to attack abnormal cells driving the disease while sparing healthy blood-forming cells.

The company said that current treatment options focus mainly on symptom management and reducing complications, rather than addressing the root cause of the disease at the cellular level.

Calytrix, based in Wellesley Hills, Massachusetts, was founded by the venture capital arm of JPMorgan Asset Management—J.P. Morgan Life Sciences Private Capital. Its investors include Westlake BioPartners and Avoro Ventures.


(To facilitate non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translations may contain errors or lack necessary context, Reuters does not guarantee the accuracy of automated translation, which is provided for reader convenience only. Reuters takes no responsibility for any damage or loss caused by your use of the automated translation feature.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!